These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9510368)

  • 1. Functional characterization of HLA-DRA1*0101/DRB1*0401 molecules expressed in Drosophila melanogaster cells.
    Hansen BE; Andersson EC; Madsen LS; Engberg J; Søndergaard L; Svejgaard A; Fugger L
    Tissue Antigens; 1998 Feb; 51(2):119-28. PubMed ID: 9510368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of peptide affinity to HLA DRB1*0401.
    Marshall KW; Wilson KJ; Liang J; Woods A; Zaller D; Rothbard JB
    J Immunol; 1995 Jun; 154(11):5927-33. PubMed ID: 7751636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles.
    Kirschmann DA; Duffin KL; Smith CE; Welply JK; Howard SC; Schwartz BD; Woulfe SL
    J Immunol; 1995 Dec; 155(12):5655-62. PubMed ID: 7499850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants.
    Monji T; McCormack AL; Yates JR; Pious D
    J Immunol; 1994 Nov; 153(10):4468-77. PubMed ID: 7525705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inefficient peptide binding by cell-surface class II MHC molecules.
    Sherman MA; Weber DA; Spotts EA; Moore JC; Jensen PE
    Cell Immunol; 1997 Nov; 182(1):1-11. PubMed ID: 9427804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC class II presentation of human acetylcholine receptor in Myasthenia gravis: binding of synthetic gamma subunit sequences to DR molecules.
    Yuen MH; Macklin KD; Conti-Fine BM
    J Autoimmun; 1996 Feb; 9(1):67-77. PubMed ID: 8845056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Counter-antigen presentation: fibroblasts produce cytokines by signalling through HLA class II molecules without inducing T-cell proliferation.
    Ohyama H; Nishimura F; Meguro M; Takashiba S; Murayama Y; Matsushita S
    Cytokine; 2002 Feb; 17(4):175-81. PubMed ID: 11991669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular mechanisms of exogenous peptide binding to HLA class II molecules in B cells.
    Frumento G; de Totero D; Ferrara GB; Chersi A; Pernis B
    Cell Immunol; 1994 Apr; 155(1):1-10. PubMed ID: 8168138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen presentation mediated by recycling of surface HLA-DR molecules.
    Pinet V; Vergelli M; Martin R; Bakke O; Long EO
    Nature; 1995 Jun; 375(6532):603-6. PubMed ID: 7540726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of HLA-DRB1-bound self-peptides following measles virus infection.
    Ovsyannikova IG; Johnson KL; Naylor S; Poland GA
    J Immunol Methods; 2005 Feb; 297(1-2):153-67. PubMed ID: 15777939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness.
    Godkin A; Davenport M; Hill AV
    Hepatology; 2005 Jun; 41(6):1383-90. PubMed ID: 15915462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peptidomimetic that specifically inhibits human leukocyte antigen DRB1*0401-restricted T cell proliferation.
    Woulfe SL; Bono CP; Zacheis ML; Welply JK; Kirschmann DA; Baudino TA; Wang Y; Stone DA; Hanson GJ; Vuletich JL; Bedell LJ; Schwartz BD; Howard SC
    J Pharmacol Exp Ther; 1997 May; 281(2):663-9. PubMed ID: 9152371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
    Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
    Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide binding to surface class II molecules is the major pathway of formation of immunogenic class II-peptide complexes for viable antigen presenting cells.
    Nygard NR; Giacoletto KS; Bono C; Gorka J; Kompelli S; Schwartz BD
    J Immunol; 1994 Feb; 152(3):1082-93. PubMed ID: 8301118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific overexpression of rheumatoid arthritis-associated HLA-DR alleles and presentation of low-affinity peptides.
    Kerlan-Candon S; Louis-Plence P; Wiedemann A; Combe B; Clot J; Eliaou JF; Pinet V
    Arthritis Rheum; 2001 Jun; 44(6):1281-92. PubMed ID: 11407687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
    Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
    Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-DR4 (DRB1*0401) transgenic mice expressing an altered CD4-binding site: specificity and magnitude of DR4-restricted T cell response.
    Pan S; Trejo T; Hansen J; Smart M; David CS
    J Immunol; 1998 Sep; 161(6):2925-9. PubMed ID: 9743354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibitory effect of altered collagen II peptide on HLA-DRB1-restricted T-cell activation.
    Cheng YJ; Zhou Q; Li ZG
    Scand J Immunol; 2005 Mar; 61(3):260-5. PubMed ID: 15787743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
    Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
    Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.